Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shengyan Zhao"'
Autor:
Shengyan Zhao, Han Deng, Ying Lu, Yiran Tao, David Li, Xiaohua Jiang, Xian Wei, Xiaofeng Chen, Fanxin Ma, Yuxi Wang, Lantu Gou, Jinliang Yang
Publikováno v:
BMC Immunology, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Leukemia inhibitory factor (LIF) is a multifunctional member of the IL-6 cytokine family that activates downstream signaling pathways by binding to the heterodimer consisting of LIFR and gp130 on the cell surface. Previous researc
Externí odkaz:
https://doaj.org/article/9c8c4ade10ee4cb397e6ac8bfe870fca
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
The “do not eat me” signaling pathway is extremely active in tumor cells, providing a means for these cells to elude macrophage phagocytosis and escape immune surveillance. Representative markers of this pathway, such as CD47 and CD24, are highly
Externí odkaz:
https://doaj.org/article/da319cd156144f5b8770174c331c236e
Autor:
Guangbing Zhang, Cuiyu Guo, Yan Wang, Xianda Zhang, Shuang Liu, Wen Qu, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu, Shengyan Zhao, Han Deng, Yuxi Wang, Lin Yu, Hongbin Yu, Yu Wu, Zhaoming Su, Pengyu Chen, Ziqing Ren, Meng Yu, Feng Qu, Yong Luo, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing potential beyond MM, which encourage
Externí odkaz:
https://doaj.org/article/a39a57a1992548e1beadb485c54a357e
Autor:
Yuyin Fu, Yujia Peng, Shengyan Zhao, Jun Mou, Lishi Zeng, Xiaohua Jiang, Chengli Yang, Cheng Huang, Yuyan Li, Yin Lu, Mengdan Wu, Yanfang Yang, Ting Kong, Qinhuai Lai, Yangping Wu, Yuqin Yao, Yuxi Wang, Lantu Gou, Jinliang Yang
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC)
Externí odkaz:
https://doaj.org/article/af80427af630405f8fdf9bb3cf41fcd4
Autor:
Weirong Lai, Shengyan Zhao, Qinhuai Lai, Wei Zhou, Mengdan Wu, Xiaohua Jiang, Xin Wang, Yujia Peng, Xian Wei, Liang Ouyang, Lantu Gou, Hao Chen, Yuxi Wang, Jinliang Yang
Publikováno v:
Journal of medicinal chemistry. 65(17)
A novel series of hybrid molecules combining pyrrolobenzodiazepine (PBD) and anthracenecarboxyimide pharmacophores were designed, synthesized, and tested for
Autor:
Zhixiong Zhang, Shengyan Zhao, Mengyao Sun, Jinliang Yang, Yuyin Fu, Weirong Lai, Yin Lu, Shijie Zhou, Mengdan Wu, Yuyan Li, Qinhuai Lai, Yujia Peng, Fan Qiao, Gou Lantu, Xiaofeng Chen, Lishi Zeng, Yiwen Zhang
Publikováno v:
BIOCELL. 45:589-597
Autor:
Yanfang Yang, Chengli Yang, Mengdan Wu, Yuxi Wang, Shengyan Zhao, Lishi Zeng, Xiaohua Jiang, Yin Lu, Qinhuai Lai, Cheng Huang, Yangping Wu, Jinliang Yang, Lantu Gou, Ting Kong, Jun Mou, Yuqin Yao, Yujia Peng, Yuyan Li, Yuyin Fu
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology
Immune checkpoint inhibitors have achieved unprecedented success in cancer immunotherapy. However, the overall response rate to immune checkpoint inhibitor therapy for many cancers is only between 20 and 40%, and even less for colorectal cancer (CRC)